Itacitinib is an orally bioavailable small-molecule inhibitor of Janus kinase 1 (JAK1). It blocks STAT phosphorylation and the production of proinflammatory factors induced by cytokines such as IL-6 and IL-23. It is studied in hematologic and lymphocytic disorders.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
INCB-039110, INCB-39110
Drug type
Small molecule
Targets
Janus kinase 1 (JAK1)
Mechanism
Inhibitor of Janus kinase 1 (JAK1)
Pathways
JAK-STAT signaling, STAT phosphorylation, proinflammatory cytokine production
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.